Bagsværd, Denmark & South San Francisco, CA — December 9, 2025 — Novo Nordisk has officially completed its acquisition of Akero Therapeutics, a clinical-stage biotech developing therapies for serious metabolic diseases including metabolic dysfunction-associated steatohepatitis (MASH). The $4.7 billion cash acquisition, plus a $0.5 billion contingent value right (CVR) tied to U.S. regulatory approval of Akero’s lead candidate efruxifermin (EFX), positions Novo Nordisk to significantly expand its pipeline in chronic liver disease.

Science Significance

This acquisition is scientifically pivotal because EFX is one of the most advanced Phase 3 therapeutic candidates for MASH, a rapidly growing metabolic disease with no currently approved treatments. The drug is being evaluated across three Phase 3 studies—SYNCHRONY Histology, SYNCHRONY Outcomes, and SYNCHRONY Real-World—designed to validate its impact on fibrosis regression and cirrhosis stabilization, two of the most clinically meaningful hallmarks of MASH. The scientific promise of EFX is reinforced by strong Phase 2b performance in the HARMONY and SYMMETRY trials, offering compelling evidence that EFX may modify underlying disease biology rather than merely managing symptoms.

Regulatory Significance

The acquisition includes a non-transferable CVR granting an additional payment upon U.S. regulatory approval of EFX for compensated cirrhosis due to MASH, emphasizing confidence in the asset’s regulatory pathway. By acquiring Akero outright, Novo Nordisk consolidates all rights needed for future regulatory submissions, commercial launch planning, and global coordination. With multiple ongoing Phase 3 trials, this transaction streamlines the regulatory trajectory under the oversight of a proven multinational innovator with extensive experience in chronic metabolic disease approvals.

Business Significance

This acquisition represents a strategic expansion into high-growth metabolic therapeutic markets, complementing Novo Nordisk’s established leadership in diabetes and obesity. The total potential transaction value of $5.2 billion signals the Company’s strong conviction in the commercial potential of EFX and the broader MASH category. Akero’s delisting from Nasdaq and integration as a wholly owned subsidiary enable full operational synergies, from clinical development to commercialization, while strengthening Novo Nordisk’s long-term revenue pipeline in chronic liver disease—a sector projected to accelerate rapidly as diagnostic rates rise.

Patients’ Significance

For patients, especially those with compensated cirrhosis or advanced fibrosis due to MASH, this acquisition could have profound implications. There are currently no FDA-approved treatments for MASH, leaving millions of patients at risk of liver failure, transplantation, and reduced quality of life. EFX’s potential to address fibrosis progression could deliver the first disease-modifying therapy, offering earlier intervention and improved long-term outcomes. The consolidation of resources under Novo Nordisk improves the likelihood of efficient clinical execution and faster availability to patients worldwide.

Policy Significance

As liver disease becomes a major public-health concern driven by obesity and metabolic disorders, this acquisition underscores the need for policy frameworks that support accelerated review and access pathways for MASH therapeutics. With the growing burden on healthcare systems, payers and regulators may need to adapt coverage policies, foster early detection programs, and enhance incentives for companies developing treatments for chronic liver diseases. This transaction also reflects increasing global recognition of MASH as a priority therapeutic area, potentially influencing future policy directions in metabolic health.

The completion of Novo Nordisk’s acquisition of Akero Therapeutics marks a transformational moment in the metabolic disease landscape, uniting a global pharmaceutical leader with one of the most promising late-stage MASH assets. As EFX advances through Phase 3 studies, this strategic integration is expected to accelerate progress toward delivering the first approved therapy for MASH. With scientific rigor, regulatory momentum, and significant commercial alignment, Novo Nordisk now stands positioned to reshape the future of liver disease treatment on a global scale.

Source: Novo Nordisk A/S press release